
PHAS
Healthcare · Biotechnology & Medical Research · $3.5M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2022
EPS trend, 90 days to now · -6.1% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 8, 2022 | Before the open | -0.35 | 0.00 | +100.0% |
| Aug 12, 2022 | Before the open | -0.31 | -0.34 | -9.7% |
| May 16, 2022 | Before the open | -0.66 | -0.23 | +65.2% |
| Mar 24, 2022 | After the close | -0.59 | -0.90 | -52.5% |
| Nov 10, 2021 | After the close | -0.61 | -0.66 | -8.2% |
| Aug 12, 2021 | Before the open | -0.46 | -0.60 | -30.4% |
| May 13, 2021 | After the close | -0.73 | -0.87 | -19.2% |
| Mar 15, 2021 | Before the open | -0.70 | -1.03 | -47.1% |
| Nov 12, 2020 | After the close | -0.77 | -0.86 | -11.7% |
| Aug 11, 2020 | After the close | -0.52 | -0.98 | -88.5% |
| May 12, 2020 | After the close | -0.37 | -0.52 | -40.5% |
| Mar 30, 2020 | Before the open | -0.40 | -0.39 | +2.5% |
| Nov 14, 2019 | Before the open | -0.37 |
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an…
| -0.40 |
| -8.1% |
| Aug 13, 2019 | After the close | -0.32 | -0.33 | -3.1% |
| May 9, 2019 | After the close | -0.41 | -0.30 | +26.8% |
| Mar 26, 2019 | After the close | -0.30 | -0.26 | +13.3% |
| Oct 19, 2018 | After the close | -0.48 | -10.45 | -2077.1% |
| Aug 29, 2018 | Time not confirmed | — | -1.34 | — |